III期非小细胞肺癌新辅助化疗疗效分析

Analysis of the effieacy of neoadjuvant chemotherapy for stage Ⅲ non-small cell lung cancer

目的 探讨III期非小细胞肺癌 (NSCLC)新辅助化疗的可行性及毒性反应并评价其有效性。方法 对 2 0 0 1年 1月～2 0 0 2年 10月 89例病例进行回顾性研究 ,其中新辅助化疗组 37例 ,对照组 5 2例。试验组给予术前NVB +DDP化疗两周期 ,对照组则直接行手术治疗。结果 新辅助化疗组有效率为 75 .6 7% (2 8/ 37) ,病期下调率为 4 3.2 4 % (16 / 37) ,手术切除率为97.2 2 % ,对照组切除率为 92 .30 % ,两组手术失血量 ,手术并发症和手术死亡率均无显著性差异。结论 术前新辅助化疗安全、有效 ,能降低III期非小细胞肺癌的病期 ,有助于提高手术切除率。

Objective To explore the feasibility and toxicity of preoperative neoadjuvant chemotherapy for non-small cell lung cancer. Methods 89 patients from Jan. 2001 to Oct. 2002 were analysed retrospectively. 37 patients(preoperative neoadjuvant chemotherapy group) were given 2 cycles of neoadjuvant chemotherapy before operation, the regimen was NVB+DDP. 52 patients were treated only by surgery as the control group, without neoadjuvant chemotherapy. Results The tumor response to induction chemotherapy was 75.67%(28/37) in preoperative neoadjuvant chemotherapy group. The tumor downstaging was 43.24%(16/37).The resection rate was 97.22% in preoperative neoadjuvant chemotherapy group, and 92.30% in control group. No significant differences in blood loss, operative complications and mortality were observed between these two groups. Conclusion The results demonstrated that the preoperative neoadjuvant chemotherapy is safe and effective. It is helpful to decrease the tumor staging, to increase the resection rate of the tumor.